https://www.businesswire.com/news/home/20260913390932/en/Zipalertinib-Plus-Chemotherapy-Demonstrates-6-Month-Median-Progression-Free-Survival-Benefit-in-REZILIENT3-Phase-3-Trial-in-First-Line-EGFR-Exon-20-Insertion-Mutation-Non-Small-Cell-Lung-Cancer 2026-09-13T23:15:00.000Z weekly 0.5 Business Wire en PressRelease 2026-09-13T23:15:00.000Z Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer CGEM https://mms.businesswire.com/media/20260913390932/en/2898981/21/Taiho_Oncology_Logo.jpg https://www.businesswire.com/news/home/20260913091795/en/Faraday-Future-Founder-and-Global-CEO-YT-Jia-Shares-Weekly-Investor-Update-Previews-the-Upcoming-919-Event-Highlights-FFs-EAI-Robotics-Autonomous-Perception-and-3D-Scanning-Technology-Adds-a-New-Senior-Advisor-Focused-on-Govt.-Procurement 2026-09-13T23:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-09-13T23:00:00.000Z Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Previews the Upcoming 9/19 Event; Highlights FF’s EAI Robotics' Autonomous Perception and 3D Scanning Technology; Adds a New Senior Advisor Focused on Govt. Procurement FFAI https://mms.businesswire.com/media/20260913091795/en/2899060/21/16x9_Clean_%283%29.jpg https://www.businesswire.com/news/home/20260913879906/en/Corgan-Expands-Aviation-Practice-in-Asia-Pacific-with-Ben-Dawson-Hire 2026-09-13T23:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-09-13T23:00:00.000Z Corgan Expands Aviation Practice in Asia Pacific with Ben Dawson Hire https://mms.businesswire.com/media/20260913879906/en/2897113/21/BenDawson.jpg https://www.businesswire.com/news/home/20260913999570/en/Definium-Therapeutics-to-Discuss-Topline-Results-from-Phase-3-Panorama-Study-in-Generalized-Anxiety-Disorder-on-September-14-2026 2026-09-13T21:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-09-13T21:00:00.000Z Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 DFTX https://mms.businesswire.com/media/20260913999570/en/2898325/21/Definium_Logo_Therapeutics_Lockup_RGB_Black_Orange.jpg https://www.businesswire.com/news/home/20260913914517/en/SESs-Final-Three-O3b-mPOWER-Satellites-Successfully-Launched 2026-09-13T20:22:00.000Z weekly 0.5 Business Wire en PressRelease 2026-09-13T20:22:00.000Z SES’s Final Three O3b mPOWER Satellites Successfully Launched SESG https://mms.businesswire.com/media/20260913914517/en/2899025/21/20260913_CC_O3b_mPOWER-F_DSC_9968.jpg https://www.businesswire.com/news/home/20260913791309/en/Wild-Alaskan-Company---Hits-Shelves-with-Nationwide-Target-Launch 2026-09-13T13:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-09-13T13:00:00.000Z Wild Alaskan Company - Hits Shelves with Nationwide Target Launch https://mms.businesswire.com/media/20260913791309/en/2898549/21/WAC_248_%282%29.jpg https://www.businesswire.com/news/home/20260913293425/en/Glenfarne-Group-Promotes-Oliver-Wood-to-Global-Head-of-Projects 2026-09-13T11:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-09-13T11:00:00.000Z Glenfarne Group Promotes Oliver Wood to Global Head of Projects https://mms.businesswire.com/media/20260913293425/en/2898799/21/oliver-wood.jpg https://www.businesswire.com/news/home/20260913549808/en/Ivonescimab-Monotherapy-Demonstrates-a-Statistically-Significant-Clinically-Meaningful-Benefit-Compared-to-Pembrolizumab-Monotherapy-in-PD-L1-Positive-Advanced-NSCLC-in-Akesos-HARMONi-2-Study-Conducted-in-China 2026-09-13T11:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-09-13T11:00:00.000Z Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China SMMT https://mms.businesswire.com/media/20260913549808/en/2824724/21/2026_SMMT_Logo_%28R%29.jpg https://www.businesswire.com/news/home/20260912948211/ja 2026-09-13T01:00:00.000Z weekly 0.5 Business Wire ja PressRelease 2026-09-13T01:00:00.000Z KOSA・MegazoneCloud、東京で韓国AI・ソフトウェア企業向けの日本進出プログラムを開催 https://mms.businesswire.com/media/20260912948211/ja/2897387/21/KOSA_jp_image.jpg